Walker V, Hollahan D, Lazdins R, Seager C. Preferences for the NovoFine®32 gauge 6mm tip in the treatment of diabetes mellitus. Can J Clin Pharmacol. 2006;13(1):e170.
Lynch P, Riedel AA, Samant N, Fan Y, Peoples T, Levinson J, Lee SW. Resource utilization with insulin pump therapy for type 2 diabetes mellitus. Am J Manag Care. 2010;16(12):892-96.
Gonder JR, Walker VM, Barbeau M, Zaour N, Zachau BH, Hartje JR, Li R. Costs and quality of life in diabetic macular edema: Canadian burden of diabetic macular edema observational study (C-REALITY). J Ophthalmol. 2014;2014:939315.
Iglay K, Cartier S, Rosen VM, Zarotsky V, Rajpathak SN, Radican L, Tunceli K. Meta-analysis of studies examining medication adherence, persistence, and discontinuation of oral antihyperglycemic agents in type 2 diabetes. Curr Med Res Opin. 2015;31(7):1283-96.
Harley C, Mishra A, Cantor SE, Nelson M, Walker AM. A ‘real world’ analysis of persistence on and adherence to glipizide GITS, glipizide IR and glibenclamide in managed care among patients with type 2 diabetes mellitus. Clin Drug Investig. 2002 Sep;22(9):575-84.
Hall J, Summers KH, Obenchain RL. Cost and utilization comparisons among propensity score-matched insulin lispro and regular insulin users. J Manag Care Pharm. 2003 May-Jun;9(3):263-68.
Shetty S, Secnik K, Oglesby AK. Relationship of glycemic control to total diabetes-related costs for managed care health plan members with type 2 diabetes. J Manag Care Pharm. 2005 Sep;11(7):559-64.
Huang ES, Basu A, Finch M, Frytak J, Manning W. . The complexity of medication regimens and test ordering for patients with diabetes from 1995 to 2003. Curr Med Res Opin. 2007 Jun;23(6):1423-30.
Riedel AA, Heien H, Wogen J, Plauschinat CA. Loss of glycemic control in patients with type 2 diabetes mellitus who were receiving initial metformin, sulfonylurea, or thiazolidinedione monotherapy. Pharmacotherapy. 2007 Aug;27(8):1102-10.
Riedel AA, Heien H, Wogen J, Plauschinat CA. Secondary failure of glycemic control for patients adding thiazolidinedione or sulfonylurea therapy to a metformin regimen. Am J Manag Care. 2007 Aug;13(8):457-63.
Harley C, Li H, Corey-Lisle P, L'Italien GJ, Carson W. . Influence of medication choice and comorbid diabetes: the cost of bipolar disorder in a privately insured US population. Soc Psychiatry Psychiatr Epidemiol. 2007 Sep;42(9):690-97.
Harley C, Gandhi SK, Heien H, McDonough K, Nelson SP. Lipid levels and low-density lipoprotein cholesterol goal attainment in diabetic patients: Rosuvastatin compared with other statins in usual care. Expert Opin Pharmacother. 2008 Apr;9(5):669-76.
Halpern R, Fuldeore MJ, Mody RR, Patel PA, Mikuls TR. The effect of serum urate on gout flare and their associated costs. J Clin Rheumatology. 2009 Feb;15(1):3-7.
Borah BJ, Darkow T, Bouchard J, Aagren M, Forma F, Alemayehu B. A comparison of insulin use, glycemic control, and health care costs with insulin detemir and insulin glargine in insulin-naive patients with type 2 diabetes. Clin Ther. 2009 Mar;31(3):623-31.
Thayer S, Arondekar B, Harley C, Darkow T. Adherence to a fixed-dose combination of rosiglitazone/glimepiride in subjects switching from monotherapy or dual therapy with a thiazolidinedione and/or a sulfonylurea. Ann Pharmacother. 2010 May;44(5):791-99.
Pollack M, Chastek B, Williams S, Moran J. Impact of treatment complexity on adherence and glycemic control: An analysis of oral antidiabetic agents. JCOM. June 2010;17(6):257-65.
Cantrell RA, Alatorre CI, Davis EJ, Zarotsky V, Le Nestour E, Cuyún Carter G, Goetz I, Paczkowski R, Sierra-Johnson J. A review of treatment response in type 2 diabetes: assessing the role of patient heterogeneity. Diab Obes Metab. 2010 Oct;12(10):845-57.
Lynch P, Riedel AA, Samant N, Fan Y, Peoples T, Levinson J, Lee SW. Improved A1C by switching to continuous subcutaneous insulin infusion from injection insulin therapy in type 2 diabetes: A retrospective claims analysis. Prim Care Diabetes. 2010 Dec;4(4):209-14.
Buysman EK, Conner C, Aagren M, Bouchard J, Liu F. Adherence and persistence to a regimen of basal insulin in a pre-filled pen compared to vial/syringe in insulin-naïve patients with type 2 diabetes. Curr Med Res Opin. 2011 Sep;27(9):1709-17.
Burke JP, Kovacs B, Borton L, Sander S. Health care utilization and costs in type 2 diabetes mellitus and their association with renal impairment. Postgrad Med. 2012 Mar;124(2):77-91.
Bergenstal RM, Fahrbach JL, Iorga SR, Fan Y, Foster SA. Preadmission glycemic control and changes to diabetes mellitus treatment regimen after hospitalization. Endocr Pract. 2012 May-Jun;18(3):371-75.
Williams SA, Buysman EK, Hulbert EM, Bergeson JG, Zhang B, Graham J. Hemoglobin A1C (HbA1c) outcomes and healthcare resource utilization in type 2 diabetes mellitus (T2DM) patients treated with combination oral antidiabetic drugs (OAD): Step-therapy, loose and fixed dose combinations. Manag Care. 2012 Jul;21(7):40-48.
Bozeman SR, Hoaglin DC, Burton TM, Pashos CL, Ben-Joseph RH, Hollenbeak CS. Predicting waist circumference from body mass index. BMC Med Res Methodol. 2012 Aug;12:115.
Williams SA, Shi L, Brenneman SK, Johnson JC, Wegner JC, Fonseca V. The burden of hypoglycemia on healthcare utilization, costs, and quality of life among type 2 diabetes mellitus patients. J Diabetes Complications. 2012 Sep-Oct;26(5):399-406.
Sullivan SD, Dalal MR, Burke JP. The impact of diabetes counseling and education: Clinical and cost outcomes from a large population of US managed care patients with type 2 diabetes. Diabetes Educ. 2013 Jul-Aug;39(4):523-31.
Burton T, Le Nestour E, Bancroft T, Neary M. Real-world comorbidities and treatment patterns of patients with acromegaly in two large US health plan databases. Pituitary. 2013 Sep;16(3):354-62.
Thayer S, Wei W, Buysman E, Brekke L, Crown W, Grabner M, Raparla S, Quimbo R, Cziraky MJ, Hu W, Cuddihy R. The INITIATOR study: pilot data on real-world clinical and economic outcomes in US patients with type 2 diabetes initiating injectable therapy. Adv Ther. 2013 Dec;30(12):1128-40.
Swindle J, Ye X, Mallick R, Song R, Horstman T, Bays HE. Colesevelam, ezetimibe, and patients with type 2 diabetes mellitus: Characteristics and clinical outcomes from a health care database. Ann Pharmacother. 2014 Jul;48(7):847-55.
Bounthavong M, Tran JN, Golshan S, Piland NF, Morello CM, Blickensderfer A, Best JH. Retrospective cohort study evaluating exenatide twice daily and long-acting insulin analogs in a Veterans Health Administration population with type 2 diabetes. Diabetes Metab. 2014 Sep;40(4):284-91.
Xie L, Zhou S, Pinsky BW, Buysman EK, Baser O. Impact of initiating insulin glargine disposal pen versus vial/syringe on real-world glycemic outcomes and persistence among patients with type 2 diabetes mellitus in a large managed care plan: A claims database analysis. Diabetes Technol Ther. 2014 Sept;16(9):567-75.
Buysman EK, Chow W, Henk HJ, Rupnow MFT. Characteristics and short-term outcomes of patients with type 2 diabetes mellitus treated with canagliflozin in a real-world setting. Curr Med Res Opin. 2015 Jan;31(1):137-43.
Buysman EK, Liu F, Hammer M, Langer J. Impact of medication adherence and persistence on clinical and economic outcomes in patients with type 2 diabetes treated with liraglutide: a retrospective cohort study. Adv Ther. 2015 Apr;32(4):341-55.
Regnier SA, Malcolm W, Haig J, Xue W. Cost-effectiveness of ranibizumab versus aflibercept in the treatment of visual impairment due to diabetic macular edema: A UK healthcare perspective. Clinicoecon Outcomes Res. 2015 May 6;7:235-47.
Khanna PP, Shiozawa A, Walker V, Bancroft T, Essoi B, Akhras KS, Khanna D. Health-related quality of life and treatment satisfaction in patients with gout disease: Results from a cross-sectional study in a managed care setting. Patient Prefer Adherence. 2015 Jul;9:971-81.
Buysman EK, Chow W, Henk HJ, Rupnow MFT. Characteristics and short-term outcomes of patients with type 2 diabetes mellitus treated with canagliflozin: a real-world analysis. BMC Endocr Disord. 2015 Nov 2;15:67.
Chow W, Buysman E, Rupnow MF, Aguilar R, Henk HJ. Canagliflozin treatment of Hispanic and non-Hispanic patients with type 2 diabetes in a US managed care setting. Curr Med Res Opin. 2016;32(1):13-22.
Burton T, Le Nestour E, Neary M, Ludlam W. Algorithm development and the clinical and economic burden of Cushing’s disease in a large US health plan database. Pituitary. 2016 Apr;19(2):167-74.
Burton T, Le Nestour E, Neary M, Ludlam W. Incidence and prevalence of acromegaly in a large US health plan database. Pituitary. 2016 Jun;19(3):262-67.
Thayer S, Chow W, Korrer S, Aguilar R. Real-world evaluation of glycemic control among patients with type 2 diabetes mellitus treated with canagliflozin versus dipeptidyl peptidase-4 inhibitors. Curr Med Res Opin. 2016 Jun;32(6):1087-96.
Haig J, Barbeau M, Ferreira A. Cost-effectiveness of ranibizumab in the treatment of visual impairment due to diabetic macular edema. J Med Econ. 2016 Jul;19(7):663-71.
Chow W, Miyasato G, Kokkotos FK, Bailey RA, Buysman EK, Henk HJ. Real-world canagliflozin utilization: Glycemic control among patients with type 2 diabetes mellitus – a multi-database synthesis. Clin Ther. 2016 Sep;38(9):2071-82.
Wei W, Buysman E, Grabner M, Xie L, Brekke L, Ke X, Chu JW, Levin PA. A real-world study of treatment patterns and outcomes in US managed-care patients with type 2 Diabetes initiating injectable therapies. Diabetes Obes Metab. 2017 Mar;19(3):375-86.
Buysman EK, Anderson A, Bacchus S, Ingham M. Retrospective study of the impact of adherence in achieving glycemic goals in type 2 diabetes mellitus patients receiving canagliflozin. Adv Ther. 2017 Apr;34(4):937-53.
Thayer S, Aquilar R, Korrer S, Chow W. HbA1c outcomes in patients with canagliflozin versus sitagliptin in US health plans. Clin Ther. 2017 Oct;39(10):2061-72.
Brekke L, Buysman E, Grabner M, Ke X, Xie L, Baset O, Wei W. The use of decomposition methods in real world treatment benefits evaluation for patients with type 2 diabetes initiating different injectable therapies: findings from the INITIATOR study. Value Health. 2017 Dec;20(10):1252-59.
Buysman EK, Sikirica MV, Thayer SW, Bogard M, DuCharme MC, Joshi AV. Real-world comparison of treatment patterns and effectiveness of albiglutide and liraglutide. J Comp Eff Res. 2018 Feb;7(2):89-100.
Gandrud L, Altan A, Buzinec P, Hemphill J, Chatterton J, Kelley T, Vojta D . Intensive remote monitoring versus conventional care in type 1 diabetes: A randomized controlled trial. Pediatr Diabetes. 2018 Feb 21; doi. 10.1111/pedi.12654 [Epub ahead of print].
Parker ED, Wittbrodt ET, McPheeters J, Frias JP. Comparison of healthcare resource utilization and costs in type 2 diabetes patients initiating dapagliflozin versus sitagliptin. Diabetes Obes Metab. 2019 Feb;21(2):227-33.
Harris S, Mohammedi K, Bertolini M, White J, Carlyle M, Zhou FL, Anderson J, Seufert J. . Patient perspectives and experiences of basal insulin (BI) titration in type 2 diabetes (T2D): A US cross-sectional survey. Metabolism. 2022;128 (Supplement):155051. https://doi.org/10.1016/j.metabol.2021.155051
Harris SB, Mohammedi K, Bertolini M, Walker V, Carlyle MH, Zhou FL, Seufert J, Anderson JE. Patient and Physician Experience of Hypoglycemia during Basal Insulin (BI) Titration in Type 2 Diabetes (T2D) in the U.S. Diabetes. 1 June 2022; 71 (Supplement_1):379–P. https://doi.org/10.2337/db22-379-P
Harris SB, Seufert J, Bertolini M, Walker V, White JC, Zhou FL, Mohammedi K, Anderson JE. Physician Perspectives and Experiences with Basal Insulin Titration in Type 2 Diabetes: A U.S. Cross-Sectional Survey. Diabetes. 1 June 2022; 71 (Supplement_1):512–P. https://doi.org/10.2337/db22-512-P
Harris SB, Mohammedi K, Bertolini M, White J, Walker V, Zhou FL, Anderson JE, Seufert J. Patient perspectives and experiences with basal insulin titration in type 2 diabetes in the United States: A cross-sectional survey. Diabetes Obes Metab. 2023 Jan 12. doi: 10.1111/dom.14973. Online ahead of print.